Antisense-mediated exon skipping agents are now approved for use in DMD, but these agents have relatively poor penetration into the myocardium and are useful for less than 25% of DMD mutations (Johnston and McNally, 2021; Sheikh and Yokota, 2022). Here, DMD is linked to Duchenne muscular dystrophy.